The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Certara, Inc. (NASDAQ:CERT) is one of the

8 Best Healthcare AI Stocks to Buy According to Analysts.

On April 22, 2026, Certara, Inc. (NASDAQ:CERT) said it entered into a definitive agreement to sell its regulatory and medical writing business to Veristat for up to $135 million. The deal is expected to close in the second quarter of 2026, subject to customary conditions. The divested unit generated $50 million in revenue and $17 million in adjusted EBITDA in 2025 and includes about 220 employees. Certara said it plans to update its 2026 guidance after the transaction closes.

On April 13, 2026, KeyBanc analyst Scott Schoenhaus lowered his price target on Certara, Inc. (NASDAQ:CERT) to $8 from $10 while maintaining an Overweight rating. The firm said the near-term setup remains largely positive ahead of Q1 earnings, although it expects most companies to reaffirm full-year guidance given macro uncertainty. KeyBanc added that healthcare utilization trends remain solid, supporting software spending, even as pharma digital advertising conditions remain uneven.

In March, UBS lowered its price target on Certara, Inc. (NASDAQ:CERT) to $10 from $15 while maintaining a Buy rating. The firm said fourth-quarter results and 2026 guidance challenged the bullish thesis, citing a services miss and slower software bookings. Despite that, UBS said Certara remains “uniquely positioned” in model-informed drug development.

Certara, Inc. (NASDAQ:CERT) provides biosimulation software and services used in drug discovery, clinical development, regulatory submissions, and commercialization.

While we acknowledge the potential of CERT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.